13F Holdings
中文EN

CDT CDT Equity Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1896212 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-70.5%
TTM EPS YoY199.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-49.2%
ROA-41.4%
ROIC (approx.)-37.1%
Asset turnover—

Leverage & solvency

Liabilities / assets14.1%
Debt / equity0.00x
Current ratio0.20x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.29x
Accruals ratio-29.5%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31
Income statement
Revenue————
R&D expense$5.05M$3.38M$90,000$37,000
SG&A expense$31.70M$12.04M$5.17M$3.05M
Operating income-$36.76M-$15.42M-$5.26M-$3.16M
Interest expense$200,000$32,000$0$100,000
Pretax income-$39.22M-$17.80M-$536,000$773,501
Income tax———$374,862
Net income-$39.22M-$17.80M-$535,000-$4.89M
EBITDA—-$15.41M——
EPS (basic)-1,177.89-61,598.62-0.79-0.13
EPS (diluted)-1,177.89-61,598.62-8.92-0.13
Weighted avg. shares (diluted)33,300289678,93937.45M
Balance sheet
Cash & equivalents$1.51M$554,000$4.23M$345,777
Short-term investments—$600,000$4.20M—
Current assets$4.38M$2.71M$5.73M$646,639
PP&E, net$269,000$40,000——
Intangibles———$5,000
Total assets$5.65M$4.19M$7.22M$5,000
Current liabilities$12.82M$10.74M$1.80M$4.18M
Total liabilities$12.82M$10.99M$7.68M$10.09M
Shareholders' equity-$7.17M-$6.79M-$457,000-$10.09M
Shares outstanding18461738,29564.63M
Cash flow statement
Operating cash flow-$15.55M-$9.68M-$7.72M-$2.27M
Capital expenditure—$51,000——
Free cash flow—-$9.73M——
Investing cash flow-$808,000-$43,000$725,000-$183,000
Financing cash flow$17.42M$6.07M$10.93M$2.45M
Depreciation & amortization—$10,000——
Stock-based compensation$2.18M$1.63M$199,000—
Share buybacks$106,000———

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.